mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease

Andrés Norambuena, Horst Wallrabe, Lloyd McMahon, Antonia Silva, Eric Swanson, Shahzad S. Khan, Daniel Baerthlein, Erin Kodis, Salvatore - Oddo, James W. Mandell, George S. Bloom

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

A major obstacle to presymptomatic diagnosis and disease-modifying therapy for Alzheimer's disease (AD) is inadequate understanding of molecular mechanisms of AD pathogenesis. For example, impaired brain insulin signaling is an AD hallmark, but whether and how it might contribute to the synaptic dysfunction and neuron death that underlie memory and cognitive impairment has been mysterious. Neuron death in AD is often caused by cell cycle reentry (CCR) mediated by amyloid-β oligomers (AβOs) and tau, the precursors of plaques and tangles. We now report that CCR results from AβO-induced activation of the protein kinase complex, mTORC1, at the plasma membrane and mTORC1-dependent tau phosphorylation, and that CCR can be prevented by insulin-stimulated activation of lysosomal mTORC1. AβOs were also shown previously to reduce neuronal insulin signaling. Our data therefore indicate that the decreased insulin signaling provoked by AβOs unleashes their toxic potential to cause neuronal CCR, and by extension, neuron death.

Original languageEnglish (US)
Pages (from-to)152-167
Number of pages16
JournalAlzheimer's and Dementia
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2017

Fingerprint

Amyloid
Cell Cycle
Alzheimer Disease
Insulin
Brain
Neurons
Asymptomatic Diseases
Poisons
Protein Kinases
Phosphorylation
Cell Membrane
mechanistic target of rapamycin complex 1
Therapeutics

Keywords

  • Alzheimer's disease
  • Amyloid-β oligomers
  • Cell cycle reentry
  • Diabetes
  • Insulin
  • Rac1
  • Tau

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Geriatrics and Gerontology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health

Cite this

Norambuena, A., Wallrabe, H., McMahon, L., Silva, A., Swanson, E., Khan, S. S., ... Bloom, G. S. (2017). mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Alzheimer's and Dementia, 13(2), 152-167. https://doi.org/10.1016/j.jalz.2016.08.015

mTOR and neuronal cell cycle reentry : How impaired brain insulin signaling promotes Alzheimer's disease. / Norambuena, Andrés; Wallrabe, Horst; McMahon, Lloyd; Silva, Antonia; Swanson, Eric; Khan, Shahzad S.; Baerthlein, Daniel; Kodis, Erin; Oddo, Salvatore -; Mandell, James W.; Bloom, George S.

In: Alzheimer's and Dementia, Vol. 13, No. 2, 01.02.2017, p. 152-167.

Research output: Contribution to journalArticle

Norambuena, A, Wallrabe, H, McMahon, L, Silva, A, Swanson, E, Khan, SS, Baerthlein, D, Kodis, E, Oddo, S, Mandell, JW & Bloom, GS 2017, 'mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease', Alzheimer's and Dementia, vol. 13, no. 2, pp. 152-167. https://doi.org/10.1016/j.jalz.2016.08.015
Norambuena, Andrés ; Wallrabe, Horst ; McMahon, Lloyd ; Silva, Antonia ; Swanson, Eric ; Khan, Shahzad S. ; Baerthlein, Daniel ; Kodis, Erin ; Oddo, Salvatore - ; Mandell, James W. ; Bloom, George S. / mTOR and neuronal cell cycle reentry : How impaired brain insulin signaling promotes Alzheimer's disease. In: Alzheimer's and Dementia. 2017 ; Vol. 13, No. 2. pp. 152-167.
@article{c926e69cc6df4cf484a9ad20108423b6,
title = "mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease",
abstract = "A major obstacle to presymptomatic diagnosis and disease-modifying therapy for Alzheimer's disease (AD) is inadequate understanding of molecular mechanisms of AD pathogenesis. For example, impaired brain insulin signaling is an AD hallmark, but whether and how it might contribute to the synaptic dysfunction and neuron death that underlie memory and cognitive impairment has been mysterious. Neuron death in AD is often caused by cell cycle reentry (CCR) mediated by amyloid-β oligomers (AβOs) and tau, the precursors of plaques and tangles. We now report that CCR results from AβO-induced activation of the protein kinase complex, mTORC1, at the plasma membrane and mTORC1-dependent tau phosphorylation, and that CCR can be prevented by insulin-stimulated activation of lysosomal mTORC1. AβOs were also shown previously to reduce neuronal insulin signaling. Our data therefore indicate that the decreased insulin signaling provoked by AβOs unleashes their toxic potential to cause neuronal CCR, and by extension, neuron death.",
keywords = "Alzheimer's disease, Amyloid-β oligomers, Cell cycle reentry, Diabetes, Insulin, Rac1, Tau",
author = "Andr{\'e}s Norambuena and Horst Wallrabe and Lloyd McMahon and Antonia Silva and Eric Swanson and Khan, {Shahzad S.} and Daniel Baerthlein and Erin Kodis and Oddo, {Salvatore -} and Mandell, {James W.} and Bloom, {George S.}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.jalz.2016.08.015",
language = "English (US)",
volume = "13",
pages = "152--167",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - mTOR and neuronal cell cycle reentry

T2 - How impaired brain insulin signaling promotes Alzheimer's disease

AU - Norambuena, Andrés

AU - Wallrabe, Horst

AU - McMahon, Lloyd

AU - Silva, Antonia

AU - Swanson, Eric

AU - Khan, Shahzad S.

AU - Baerthlein, Daniel

AU - Kodis, Erin

AU - Oddo, Salvatore -

AU - Mandell, James W.

AU - Bloom, George S.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - A major obstacle to presymptomatic diagnosis and disease-modifying therapy for Alzheimer's disease (AD) is inadequate understanding of molecular mechanisms of AD pathogenesis. For example, impaired brain insulin signaling is an AD hallmark, but whether and how it might contribute to the synaptic dysfunction and neuron death that underlie memory and cognitive impairment has been mysterious. Neuron death in AD is often caused by cell cycle reentry (CCR) mediated by amyloid-β oligomers (AβOs) and tau, the precursors of plaques and tangles. We now report that CCR results from AβO-induced activation of the protein kinase complex, mTORC1, at the plasma membrane and mTORC1-dependent tau phosphorylation, and that CCR can be prevented by insulin-stimulated activation of lysosomal mTORC1. AβOs were also shown previously to reduce neuronal insulin signaling. Our data therefore indicate that the decreased insulin signaling provoked by AβOs unleashes their toxic potential to cause neuronal CCR, and by extension, neuron death.

AB - A major obstacle to presymptomatic diagnosis and disease-modifying therapy for Alzheimer's disease (AD) is inadequate understanding of molecular mechanisms of AD pathogenesis. For example, impaired brain insulin signaling is an AD hallmark, but whether and how it might contribute to the synaptic dysfunction and neuron death that underlie memory and cognitive impairment has been mysterious. Neuron death in AD is often caused by cell cycle reentry (CCR) mediated by amyloid-β oligomers (AβOs) and tau, the precursors of plaques and tangles. We now report that CCR results from AβO-induced activation of the protein kinase complex, mTORC1, at the plasma membrane and mTORC1-dependent tau phosphorylation, and that CCR can be prevented by insulin-stimulated activation of lysosomal mTORC1. AβOs were also shown previously to reduce neuronal insulin signaling. Our data therefore indicate that the decreased insulin signaling provoked by AβOs unleashes their toxic potential to cause neuronal CCR, and by extension, neuron death.

KW - Alzheimer's disease

KW - Amyloid-β oligomers

KW - Cell cycle reentry

KW - Diabetes

KW - Insulin

KW - Rac1

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=85005981036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005981036&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2016.08.015

DO - 10.1016/j.jalz.2016.08.015

M3 - Article

C2 - 27693185

AN - SCOPUS:85005981036

VL - 13

SP - 152

EP - 167

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -